399 related articles for article (PubMed ID: 35204653)
1. The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.
Kumar AA; Buckley BJ; Ranson M
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204653
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
3. Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Tincknell G; Piper AK; Aghmesheh M; Becker T; Vine KL; Brungs D; Ranson M
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439251
[TBL] [Abstract][Full Text] [Related]
4. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
5. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA.
He X; Zheng Z; Li J; Ben Q; Liu J; Zhang J; Ji J; Yu B; Chen X; Su L; Zhou L; Liu B; Yuan Y
Carcinogenesis; 2012 Mar; 33(3):555-62. PubMed ID: 22223849
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
7. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
8. Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group.
Hildenbrand R; Niedergethmann M; Marx A; Belharazem D; Allgayer H; Schleger C; Ströbel P
Am J Pathol; 2009 Jun; 174(6):2246-53. PubMed ID: 19435784
[TBL] [Abstract][Full Text] [Related]
9. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
10. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Asuthkar S; Stepanova V; Lebedeva T; Holterman AL; Estes N; Cines DB; Rao JS; Gondi CS
Mol Biol Cell; 2013 Sep; 24(17):2620-32. PubMed ID: 23864708
[TBL] [Abstract][Full Text] [Related]
11. The urokinase plasminogen activator system: a target for anti-cancer therapy.
Ulisse S; Baldini E; Sorrenti S; D'Armiento M
Curr Cancer Drug Targets; 2009 Feb; 9(1):32-71. PubMed ID: 19200050
[TBL] [Abstract][Full Text] [Related]
12. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
[TBL] [Abstract][Full Text] [Related]
13. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
15. The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Baldini E; Sorrenti S; D'Armiento E; Di Matteo FM; Catania A; Ulisse S
G Chir; 2012 Oct; 33(10):305-10. PubMed ID: 23095556
[TBL] [Abstract][Full Text] [Related]
16. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells.
Gorantla B; Asuthkar S; Rao JS; Patel J; Gondi CS
Mol Cancer Res; 2011 Apr; 9(4):377-89. PubMed ID: 21389187
[TBL] [Abstract][Full Text] [Related]
17. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
Cantero D; Friess H; Deflorin J; Zimmermann A; Bründler MA; Riesle E; Korc M; Büchler MW
Br J Cancer; 1997; 75(3):388-95. PubMed ID: 9020484
[TBL] [Abstract][Full Text] [Related]
18. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
19. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
20. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
